Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.

被引：0
|
作者：
Schoen, Martin W.
Carson, Kenneth Robert
Luo, Suhong
Eisen, Seth
Reimers, Melissa Andrea
Drake, Bettina F.
Bennett, Charles L.
Knoche, Eric Marshall
Yan, Yan
Sanfilippo, Kristen Marie
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] St Louis Vet Affairs Med Ctr, Res Serv, St Louis, MO USA
[3] St Louis Vet Affairs Med Ctr, St Louis, MO USA
[4] Washington Univ, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Med, Div Med Oncol, St Louis, MO 63110 USA
[6] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO 63110 USA
[7] South Carolina Coll Pharm, Columbia, SC USA
[8] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA
[9] Washington Univ, Barnes & Jewish Hosp, St Louis, MO 63110 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5032
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
    George, Daniel J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Russell, David
    Schultz, Neil M.
    Janjan, Nora
    Freedland, Stephen J.
    FUTURE ONCOLOGY, 2022, 18 (34) : 3783 - 3790
  • [22] Clinical outcomes in metastatic prostate adenocarcinoma treated with abiraterone and enzalutamide
    Soomro, Misbah Younus
    Khan, Saqib Raza
    Ishfaq, Hashim
    Ali, Insia
    Samar, Mirza Rameez
    Hameed, Arif
    Zehra, Nawazish
    Moosajee, Munira
    Rashid, Yasmin Abdul
    ECANCERMEDICALSCIENCE, 2024, 18
  • [23] Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
    Caram, Megan E. V.
    Borza, Tudor
    Min, Hye-Sung
    Griggs, Jennifer J.
    Miller, David C.
    Hollenbeck, Brent K.
    Mukherjee, Bhramar
    Skolarus, Ted A.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (08) : E694 - E702
  • [24] Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    de Wit, Ronald
    de Bono, Johann
    Sternberg, Cora N.
    Fizazi, Karim
    Tombal, Bertrand
    Wuelfing, Christian
    Kramer, Gero
    Eymard, Jean-Christophe
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerdur
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Castellano, Daniel
    de Wit, Ronald
    de Bono, Johann
    Sternberg, Cora N.
    Fizazi, Karim
    Tombal, Bertrand
    Wulfing, Christian
    Kramer, Gero
    Eymard, Jean-Christophe
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerour
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Castellano, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26): : 2506 - 2518
  • [25] PSA Progression and survival in mCRPC patients treated with abiraterone or enzalutamide
    Lopez Campos, F.
    Lorente, D.
    Llacer Perez, C.
    Gomez-Iturriaga, A.
    Henriquez-Lopez, I.
    Peleteiro, P.
    Ramirez-Backhaus, M.
    Navarro-Castellon, J.
    Lozano, R.
    Romero, N.
    Gajate, P.
    Ana, C.
    Gomez, J.
    Alvarez, S.
    Molina-Cerrillo, J.
    Pelari, L.
    Hernandez-Corrales, A.
    Morillo, V.
    Garcia, R.
    Ferrer-Albiach, C.
    Castro, E.
    Olmos, D.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S750 - S751
  • [26] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [27] Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (May, 10.1038/s41391-023-00680-4, 2023)
    Schoen, Martin W.
    Carson, Kenneth R.
    Eisen, Seth A.
    Bennett, Charles L.
    Luo, Suhong
    Reimers, Melissa A.
    Knoche, Eric M.
    Whitmer, Alison L.
    Yan, Yan
    Drake, Bettina F.
    Sanfilippo, Kristen M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (04) : 811 - 811
  • [28] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
  • [29] Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.
    Hahn, Andrew W.
    Ledet, Elisa
    Stenehjem, David D.
    Nussenzveig, Roberto
    Braithwaite, Matthew
    Maughan, Benjamin Louis
    Lilly, Michael B.
    Sartor, A. Oliver
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Treatment of metastatic castration-resistant prostate cancer. Drug interaction potentials of abiraterone acetate and enzalutamide
    Lipp, H-P.
    Miller, K.
    UROLOGE, 2016, 55 (06): : 766 - 771
12345